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Food allergies are recognized as a global health concern. In order to protect
allergic consumers from severe symptoms, allergenic risk assessment for
well-known foods and foods containing genetically modiﬁed ingredients is
installed. However, population is steadily growing and there is a rising need to
provide adequate protein-based foods, including novel sources, not yet used
for human consumption. In this context safety issues such as a potential
increased allergenic risk need to be assessed before marketing novel food
sources. Therefore, the established allergenic risk assessment for genetically
modiﬁed organisms needs to be re-evaluated for its applicability for risk
assessment of novel food proteins. Two diﬀerent scenarios of allergic
sensitization have to be assessed. The ﬁrst scenario is the presence of already
known allergenic structures in novel foods. For this, a comparative
assessment can be performed and the range of cross-reactivity can be
explored, while in the second scenario allergic reactions are observed toward
so far novel allergenic structures and no reference material is available. This
review summarizes the current analytical methods for allergenic risk
assessment, highlighting the strengths and limitations of each method and
discussing the gaps in this assessment that need to be addressed in the near
future.
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1. Introduction
IgE-mediated food allergies are regarded
as a relevant health concern and aﬀect
up to 0.1–3.2% adults and 0.1–5.7%
children in Europe.[1] It is only a limited
number of foods that induce an immune
response in the majority of predisposed
individuals. However, upon contact,
allergics can develop rather mild up to
severe, even life-threatening reactions to
minute amounts of the causative source.
In order to protect allergic consumers,
allergenic risk assessment has been in-
stalled. For Europe a list of 14 most com-
monly allergenic foods and food groups
(milk, egg, ﬁsh, crustaceans, molluscs,
tree nuts, peanut, soy, wheat, lupine,
sesame, mustard, celery, and sulﬁt (for
hypersensitivity reasons)) has been es-
tablished and labeling of these foods is
mandatory when used as ingredients.
Furthermore, for genetically mod-
iﬁed organism (GMO)-derived foods
allergenic risk assessment has been
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Figure 1. Flow chart on current risk assessment approach for GMO risk
assessment adopted for novel foods from EFSA.[2,4,25] Allergenic risk as-
sessment of novel foods focusing on allergenic cross reactive structures.
established by the European Food Safety Authority (EFSA;
Figure 1).[2,3] This risk assessment has been developed within the
past two decades and is currently based on a weight of evidence
approach. The current GMO risk assessment includes several
steps. The newly introduced gene and its product are checked
for potential sequence and/or structure similarity to known al-
lergens. In parallel, sera from allergic donors are applied in in
vitro assays to investigate whether signiﬁcant higher IgE bind-
ing is observed in the GMO-product as compared to its isogenic
counterpart (speciﬁc serum screening). Furthermore, stability of
proteins against gastric and duodenal digestion is analyzed, since
prolonged stability of proteins may increase the allergenic activ-
ity versus labile proteins, which are easily degraded into peptides.
Also proteins may vary in their stability when exposed to thermal
or chemical treatment; increased resistance may point toward an
elevated allergenic risk. Finally, for allergenic risk assessment of
GMO foods the comparative compositional analysis of the GM
organism versus the isogenic line or appropriate comparators is
required.
Since there is a rising need to provide protein sources to feed a
steadily growing population, novel sources such as algae and in-
sects are currently explored for safe human consumption. In this
context assessing a potential allergenic risk is mandatory before
marketing novel food sources.[4] Prior to assessing the allergenic
risk of novel non-GMO foods or proteins with so far unknown al-
lergenic activity, the valuable existing knowledge about allergenic
risk assessment forGMOsneeds to be re-evaluated for its applica-
bility for risk assessment of novel food proteins. Hence, the prin-
ciples of allergenic risk assessment of GMO will be gauged for
their applicability on the assessment of novel foods in this review.
Furthermore, the analytical methods applied in this risk assess-
ment will be summarized and recent advances in the method-
ology highlighted. Also, gaps of knowledge and methodological
limitations identiﬁed within this assessment will be discussed.
Moreover, the available tools for allergenic risk assessment of
potential allergenic food proteins with cross-reactivity to known
allergens may not be applicable for unknown proteins having al-
lergenic potential. Thus, to assess the de novo sensitizing capac-
ity of such novel foods, in vivo testing in animals, or cell culture
systems have been proposed and some have shown experimental
evidence of principle applicability. However, various challenges
of developing and designing animal models and the most im-
portant considerations of species and strains, diet, route of ad-
ministration, relevant controls, and endpointmeasures exist, and
have been recently reviewed by Bogh et al.[5] Furthermore, cellu-
lar systems such as dendritic cell activation assays have been used
to investigate whether the interaction of food and food compo-
nents with immune cells points toward sensitization or tolerance
induction.[6–9] Yet, the great majority of these novel methods are
not generally available or available at all. Thus, this review focuses
on the current knowledge and application of existing and estab-
lished qualitative and quantitative analytical methods for use in
allergenic risk assessment of both food extracts and individual
food proteins.
In the following subsections, currently applied methods for
puriﬁcation of allergens fromnatural food sources as well as their
production as recombinant proteins will be summarized. Sub-
sequently, the analytical methods to assess the physicochemical
and immunochemical properties are presented, including 2DE
coupled with MS, determination of primary, secondary, and ter-
tiary structure of proteins, and IgE-assays investigating the aller-
genic activity of proteins. For IgE-binding assays targeted serum
screening, that is applying sera from patients with established
speciﬁc IgE response to the target food, is essential. In addition,
the biological relevance of this speciﬁc IgE response can be in-
vestigated by basophil activation assays.
In principle two diﬀerent scenarios of allergic sensitization
have to be assessed. The ﬁrst scenario is the presence of already
known or homologous (pan-) allergenic structures in novel foods
(cross-reactivity). In this case a comparative and targeted assess-
ment can be performed and the range of cross-reactivity can be
explored (Figure 1). In the second scenario allergic reactions are
observed toward so far novel allergenic structures and no refer-
ence material is yet available (Figure 1). Also, no prospective tar-
get serum screening can be performed.[4] As mentioned above,
for the latter scenario well-deﬁned and predictive cellular assays
and animal models are missing.
Hence, this review summarizes the current methods estab-
lished and applied for in vitro testing, highlighting the advan-
tages and the limitations of each methodology for the allergenic
risk assessment of novel food proteins. Both sensitization scenar-
ios are taken into account to identify methods and gaps alike, and
to provide information whether themethodology is applicable for
single proteins only or for proteins within complex foodmatrices
(Tables 1 and 2).
1.1. Food Extracts and Puriﬁed Allergens
1.1.1. Production of Extracts and Identiﬁcation of Allergenic
Components
For allergenicity assessment of novel foods, preparation of
an extract[10] is the ﬁrst step, representing all the substances
present in the commercial food product, including allergenic
and nonallergenic compounds embedded in the food matrix.
In fact, it is desirable that the protein extract is made from the
processed food as it is consumed, trying to include all possible
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Table 2. Gaps identiﬁed in the current risk assessment and recommendations for further research
Methods and tools Features and limitations Recommendations for further research
Allergen databases Diﬀerent databases provide diﬀerent levels of information;
some of them are not regularly updated/curated, and
therefore relevant information is missing or available
information outdated
Inclusion criteria for allergenic proteins vary for individual
databases
Linking of existing (allergen) databases; harmonization of
inclusion criteria for allergens
Experimental studies in B- and T-cell epitopes and
implications on cross- reactivity
Improving predictive algorithms for sensitizing potential of
proteins linked with and without clinical relevance
Analytical methods Highly sensitive and advanced methods available for protein
characterization
Sample preparation especially for complex food extracts is
sometimes diﬃcult (lack of harmonized protocols)
Harmonization of method protocols; improvements in
sample preparation; generation of scientiﬁc evidence of
certain structural determinants (glycosylation, aggregation,
etc.) linked with increased allergenicity, which is currently
lacking
IgE binding assays Well standardized reference assays including reference
proteins are missing. In case of novel proteins, no reference
material is available; if sIgE is not available, animal derived
antibodies can be used
Identiﬁcation and generation of suitable reference proteins
Digestion assays Diﬀerent protocols for protein digestion are available;
however, harmonized protocols are needed; lack of
guidance on how to interpretate data, and lack of reference
material; evidence of linking protein stability and de novo
sensitization is missing
Development of reference materials and harmonized
protocols
Performance of harmonized digestion assays in ring trials
with reference materials
Animal studies on comparative digestion and de novo
sensitization
Food processing techniques Knowledge on food processing and its impact on allergenicity
is incomplete on a qualitative and quantitative level.
Limited knowledge about the most eﬀective methods
(combinations), including novel processing techniques
More data on processed food proteins and their allergenicity
required; to identify the most important (combination of)
processing techniques with an impact on allergenicity
Food matrix Analytical methods are established—but limited data are
available showing a link of food matrix components to
allergenicity;
limited knowledge available about food components and their
interaction with allergens
Studies required on food matrix composition and interaction
with individual food proteins in model systems;
identiﬁcation of relevant immunomodulating food matrix
components
Biological assays Cellular and animal models are established but reliable assays
for detection of de novo sensitization are lacking.
Method development to assess protein ligand binding and
impact on innate and adaptive immune responses;
identiﬁcation of biomarkers for de novo sensitization
modiﬁcations that could alter the allergenicity. Furthermore,
it is important to note that these food extracts may contain
(nonproteinaceous) compounds with immunological activity,
such as pollen associated lipid molecules in pollen, or secondary
metabolites in plants (ﬂavonols and alkaloids).
Usually, these extracts consist of hydrophilic complexmixtures
including, proteins, nucleic acids, sugars, and diverse compo-
nents of the extracellular matrix. Their chemical nature and ratio
depend on the origin of the extract. For example, a fruit extract
obtained by PBS, contains only 1–5% protein of the dry weight,
while the remaining content is mostly sugars. In this case, it is
recommended to carry out a selective precipitation for proteins
(i.e., with ammonium sulfate or with phosphotungstic acid) to
improve their further puriﬁcation and characterization.[11]
However, for the allergenic characterization of extracts mostly
proteins account for the IgE binding activity. In most cases, sim-
ple buﬀers such as PBS or TRIS (pH 7.4) are used, extracting only
the readily soluble proteins from the food product.[10] But pro-
teins display a range of diﬀerent characteristics, and therefore,
the selection of the pH and/or the salt concentration of the ex-
traction buﬀer is crucial. For example, extraction performed with
PBS pH 7.0, usually yields 80–90% of soluble protein content,
while, 10–20% are missed.[11] However, nonspeciﬁc lipid trans-
fer proteins (nsLTPs) are soluble at acidic pH (less than 4), while
their extraction is reduced down to 40% under neutral pH 7.0
conditions.
Yet, it is also important to determine the optimum conditions
to collect allergens from their target food source (e.g. peanut ﬂour
versus ground peanut[12]). The food matrix used (e.g. fatty sub-
stances) can delay absorption, thus aﬀecting the time interval
associated to a reaction, or it may aﬀect the intrinsic allergenic
properties of the food.[13] Hence, it is important to understand
how the composition of the food aﬀects the elicitation of a reac-
tion. Therefore, all these factors should be taken into consider-
ation to obtain an extract or complementary extracted fractions
that provide a good picture of the novel food. Finally, throughout
the extraction procedure endogenous proteoloytic activity must
be considered and inactivated if necessary.
1.1.2. Puriﬁcation of Allergens
In addition to characterizing total food extracts, puriﬁcation of
target proteins is required. Chemical modiﬁcations of allergens
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may happen during the isolation process. For example, seed stor-
age proteins in plants, such as those associated with lipid bod-
ies as oleosins, or deamidation of wheat proteins, may result in
structural changes during the puriﬁcation process. Therefore, it
is important to know the nature of the target protein to be puri-
ﬁed, and design the least harmful puriﬁcation protocol.
Puriﬁcation of allergens/proteins is mostly performed by a se-
ries of diﬀerent extraction and chromatographic techniques.[13,14]
Chromatography is based on the principle of selective retention,
which aims to separate the components of a mixture, identify-
ing them, and determining their amounts. There are four main
types. Exclusion molecular chromatography (also molecular ﬁl-
tration) separates components by molecular mass. It has low
resolution and is usually employed as an initial step in the pu-
riﬁcation process. Ion exchange chromatography allows separa-
tion based on the charge of molecules. Elution is carried out by
changing the ionic strength in the mobile phase, either modi-
fying pH or increasing salt concentration. RP chromatography
is based on repulsive hydrophobic forces arising from interac-
tions among a relatively polar solvent, a relatively nonpolar com-
pound, and a nonpolar stationary phase. Proteins in the sam-
ple are denatured at acidic pH exposing, thus, their hydropho-
bic regions that are instrumental for separation by polarity. Non-
polar (hydrophobic) regions remain retained longer and are
eluted later than polar (hydrophilic) regions. Aﬃnity chromatog-
raphy is used when speciﬁc antibodies are available, and target
protein is only available on low concentration in the starting
mixture.
Once the allergen has been isolated and puriﬁed, the identity
and the level of purity need to be assessed. In this regard, amino-
terminal sequencing (increasingly obsolete) and identiﬁcation by
peptidemass ﬁngerprinting andMS are themost frequently used
techniques[14] (see also sub-section 1.2.2 on protein characteri-
zation by proteomics and mass spectrometry). In addition, size
exclusion chromatography (SEC) is indicative if comigrating pro-
teins are present in the preparation. Also, further information is
needed whether the protein is still in its “native” structure, with
respect to aggregation status and/or solubility or potential loss of
relevant isoforms etc. (see also Section 1.2).
1.1.3. Recombinant Protein Production and Puriﬁcation
When puriﬁcation of allergens from natural sources yield low
amounts or is too complex, heterologous expression of allergens
represents an alternative. Relatively large amounts (mg–g) of al-
lergens can be produced from heterologous expression systems,
potentially with the same biological activity as the natural coun-
terpart. Frequently, the target protein is obtained by cloning and
expressing the allergen encoding gene in bacteria (Escherichia
coli) or yeast (Saccharomyces cerevisiae and Pichia pastoris), plants,
or other eukaryotic cell systems.[15–18]
Selection of the optimal expression system depends on the
gene involved. For example, S. cerevisiae is often preferred for
proteins that require signiﬁcant posttranslational modiﬁcation
while insect or mammal cell lines are used when human-like
splicing of mRNA is needed. Nonetheless, bacterial expression
usually has the advantage of easily producing large amounts of
target protein as required by X-ray crystallography or NMR spec-
troscopy techniques for structure determination. However, since
prokaryotes are not equipped with the full enzymatic machinery
to accomplish posttranslational modiﬁcations, multidomain eu-
karyotic proteins expressed in bacteria are often nonfunctional.
In addition,many proteins become insoluble as inclusion bodies.
Consequently, it is very diﬃcult to recover themwithout harsh de-
naturants and cumbersome protein refolding procedures need to
be performed.[19]
To address these shortcomings, eukaryotic expressions sys-
tems have been developed: cells of plants (e.g. tobacco), insects,
or mammals are transfected with the target genes and cultured
in suspension or even as tissues or whole organisms to produce
properly folded proteins. However, in vivo mammalian expres-
sion systems show low yield and other limitations (time consum-
ing, toxicity to host cells, etc.). Other expression systems that
use unicellular eukaryotes are being developed with the aim of
combining high yield production and scalable features of bac-
teria or yeast proteins with the advanced epigenetic features of
plants, insects, or mammals. However, these new systems may
present an additional risk of allergenic contamination. Puriﬁca-
tion of expressed proteins could drag contaminants that act as
allergens through cross-reactivity.[20] After having successfully es-
tablished the recombinant production, the respective puriﬁca-
tion protocol needs to be developed to obtain a highly pure ho-
mogenous protein batch. The expression system and the puriﬁ-
cation process may impact the overall structural integrity and
thus allergenic activity. Thus, the recombinant protein should
be compared to its natural counterpart, at least when present
in an optimized extract, to allow interpretation of its biological
activity.
1.1.4. Detection and Characterization of Allergens
1.1.4.1. Food Extracts. To characterize the composition of total
food extracts a range of analytical methods can be applied like
2DE followed by MS or LC–MS. For allergenic GMO-risk assess-
ment comparator extracts are available. However, this is not an
option for novel food extracts. Then only batch to batch variation
can be assessed and potential marker allergens based on homol-
ogy screening or MS analysis can be identiﬁed. See also the re-
spective sub-section 1.2.2 on proteomics.
1.1.4.2. Puriﬁed Proteins. For puriﬁed natural and recombi-
nant proteins the level of purity needs to be determined and
additional protein contaminations with and without allergenic
activity identiﬁed. Also the range of potential isoforms with vary-
ing IgE binding capacity needs to be deﬁned as a reference set
of proteins.[21,22] Especially for recombinant proteins lipopolysac-
charide (LPS) contamination should be ruled out since this could
aﬀect further immunization/sensitization studies. Subsequently,
recombinant proteins have to be checked for their physicochem-
ical equivalence to their natural counterpart, that is: do they pro-
vide the same posttranslational modiﬁcations, such as glycosyla-
tion pattern, biological activity, processed/mature protein, correct
3D structure etc.
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1.2. Allergen Identiﬁcation: Primary, Secondary, and Tertiary
Structure Determination of Allergens (Bioinformatics, LC–MS,
CD, and FTIR)
1.2.1. Allergen Databases
It is well known that only a minority of all known proteins iden-
tiﬁed so far display allergenic activity and these can be assigned
to approximately 2% of all known protein families.[23] Within the
last decade eﬀorts have been undertaken to set up a number of
allergen databases collecting and curating the existing data of
allergen sequences such as the IUIS allergen database (www.
allergen.org), AllergenOnline (http: //www.allergenonline.org),
Allergome (http://www.allergome.org/), ALLFam (http://www.
meduniwien.ac.at/allfam/), and theCOMPAREdatabase (http://
comparedatabase.org/). The IUIS database provides the system-
atic nomenclature for allergens and is supervised and updated
by a speciﬁc committee.[24] Allergenonline provides access to a
peer reviewed allergen list and sequence searchable database in-
tended for the identiﬁcation of proteins that may present a po-
tential risk of allergenic cross-reactivity. The Allergome database
provides a comprehensive, nonpeer-reviewed collection of infor-
mation on allergenic proteins, while in the ALLFam database
allergens are grouped according to their protein family charac-
teristics. Recently HESI released the COMPARE 2017 Database,
a new transparent resource for the identiﬁcation of protein se-
quences including known and putative allergens. Current aller-
genic risk assessment requires the analysis of the primary se-
quence from a target protein and to assess potential sequence
similarity to known allergens.[25] The alignment based criterion
between target protein and already known allergen has been set
for 35% sequence identity over a sliding window of 80 amino acid
(aa) residues. In addition, several bioinformatics approaches are
under development looking for certain motifs or peptides that
may contribute to a more precise in silico assessment. It is gen-
erally agreed that the quality and reliability of allergen databases
are based on their regular updates and continuous curation.With
regard to allergenic risk assessment of novel foods, this in silico
analysis can only provide information for proteins similar to al-
ready known allergens. For any other not yet identiﬁed protein
this assessment cannot be applied. Whether new algorithms as-
sessing motifs and/or certain peptides related to an increased al-
lergenic activity will improve the current assessment remains to
be determined.
1.2.2. Primary Sequence Analysis of Allergens Using MS and
Application of Proteomics
The fast evolution of MS and liquid separation techniques high-
lights promising tools for both, multidetection of known aller-
gens in complex matrices as well as for in-depth characterization
of physico-chemical properties.[26] These analyses are also rele-
vant for the quantiﬁcation of allergens in food products and rep-
resent the key information for allergen labeling thereof.
Together with crystallographic and NMR-based approaches,
MS analysis is used for in-depth allergen characterization.[27] It
includes the study of (a) the primary protein sequence of a target
allergen, (b) posttranslational and post food processingmodiﬁca-
tions, (c) molecular interactions, and (d) structural studies. Pri-
mary sequence determination is performed by MS to unambigu-
ously identify allergens. Advanced sequencingmethods combine
database search and de novo sequencing experiments together
with bottom-up, in which the proteins are digested with trypsin to
obtain peptides, middle-down approach, which produces limited
digest (e.g., Glu-C or Asp-N), and ﬁnally the top-down approach,
which is able to analyze the intact sample without any treat-
ment digestions, which was used for polymorphism studies[28]
evaluating the resistance of allergens against proteolysis[29] and
for sequence homology driven detection of yet unsequenced
allergens.[30]
The detection, identiﬁcation, and localization of allergen mod-
iﬁcations require most of the time extensive MS fragmentation
capabilities based on diﬀerent activation techniques and puriﬁed
proteins. It is also useful for the comparison of native and recom-
binant proteins. For example, theN–glycome proﬁling of patatins
was performed by the enzymatic release of glycans, followed
by chemical derivatization and subsequent MS analyses.[31] The
study of Halim et al. highlighted novel PTMs in major inhalant
allergenic proteins.[32] Recent studies were performed on the de-
tection of advanced glycation end products (AGEs) as well as for
the application of related bioinformatic tools.[33,34] Structural in-
formation can be extracted from experiments using ion-mobility
MS and hydrogen deuterium exchange (HDX-MS) studies.[35,36]
Willison et al. successfully applied HDX-MS to determine the
conformational epitope of Pru du 6.0201, a major allergen from
almond.[37] Intact proteins can be analyzed in the gas phase under
a shape similar to that in solution (native MS). Native separation
methods such as CE coupled toMS using top down identiﬁcation
strategy is a promising trend of MS.[38,39] Also online digestion of
native proteins may lead to fast epitope mapping.
Proteomics is able to reveal the presence/absence of allergens
and thus represents a useful tool to study the composition and
the nature of food allergens.[40,41] Furthermore, the areas of an
allergen interacting with IgE antibodies, so-called B-cell epitopes,
can be determined. Linear epitopes, representing the primary se-
quence of the allergenic protein are resistant to thermal treat-
ments and thus can be recognized even after reduction processes.
In contrast, conformational epitopes are related to secondary and
tertiary structure of the protein, are thermo-labile, and therefore,
their identiﬁcation after protein reduction may not be possible
using MS techniques.[42]
The strategies in proteomics to detect food allergens are ba-
sically two: one is based on a gel approach while the other rep-
resents a gel-free approach. The gel-based approach includes
1DE and 2DE followed by immunoblotting and MS to identify
the protein spots. The gel-free approach is based on HPLC–
MS/MS and subsequent IgE binding assay of the trypsinized
proteome. Bioinformatic analysis is needed for the prediction
of speciﬁc immunoreactive epitopes in both approaches. Previ-
ously, several studies reported the successful detection of aller-
gens in foods using a 2D-immunoblotting experimental design,
in beer,[41] beef,[42] milk,[43,44] rice,[45] ﬁsh,[46] and so on. As men-
tioned above glycans can trigger IgE-based immune reactions. In
meat, mostly alpha-Gal is responsible for allergic reactions. The
work of Apostolovic and colleagues identiﬁed novel alpha-Gal-
containing proteins by 2DE.[42] Fish is one of the most frequent
causes of IgE-mediated food allergy and is a good example for the
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application of proteomics in food allergen detection and modu-
lation. Jamaluddin et al. published a study about parvalbumins
in the longtail tuna (Thunnus tonnggol). In addition to the parval-
bumin identiﬁcation two newmajor thermolabile allergens were
identiﬁed as creatine kinase and enolase.[47] Another interesting
approach was performed by Rodrigues et al., whomodulated par-
valbumin expression in ﬁsh muscle. Gel-based proteomics was
used to follow the modulation of parvalbumin expression in the
European seabass fed with speciﬁcally designed low-allergen di-
ets to be used for farmed ﬁsh production.[48]
The possibility to detect allergens even in trace amounts in
complex food matrices is challenging. It is well-known that also
little quantities, not indicated in the food label, could represent
a serious burden for highly sensitive allergic patients. Recently,
huge progress in allergen quantiﬁcation has been made by the
use of Multiple Reaction Monitoring MS (MRM–MS). Speciﬁc
peptide signatures derived from allergens can be quantiﬁed by
Selected Reaction Monitoring acquisition (SRM) or MRM and
the use of internal peptide standards.[49] A recent tendency in
the ﬁeld of MS based quantitative analyses relies on the use
of High Resolution full scan MS acquisition (HR-MS). This
acquisition mode renders possible comprehensive analyses in a
non-targeted approach. Korte et al. applied thismethod formulti-
allergen detection screening with the additional option for retro-
spective detection.[50] Koeberl and colleagues developed amethod
for the quantiﬁcation, using MRM.[51] They authored an interest-
ing paper where they reported pro and cons of both, immunolog-
ical and MS methods and highlighted the importance of crucial
selection of each antigen of signature peptides and related tran-
sitions. Moreover, Houston and colleagues[52] succeeded in the
detection of the concentration of ten allergens in commercial soy-
bean varieties using a label free proteomics approach. By using
MRM approach, they were able to measure antigens in the range
between 0.5 and 0.7 μg mg–1. They used BSA as an internal stan-
dard in order to reduce the technical variance up to 7%. Another
example is the fast detection of ﬁsh allergen parvalbumin (one of
the major allergens in ﬁsh) described by Carrera and colleagues
who proposed a selectedMS/MS ionmonitoring (SMIM) in a lin-
ear ion trap (LIT) mass spectrometer, which can be performed in
less than 2 h.[53]
1.2.3. Secondary Structure Determination of Proteins: CD and FTIR,
and X-Ray and NMR
Basic Principles of CD Spectroscopy: Circular dichroism (CD) spec-
troscopy has become an invaluable research technique for gain-
ing information about protein structure, dynamics, and inter-
actions with both, other proteins and ligands, respectively.[54]
Two basic types of information can be obtained from CD
spectra:
 Secondary structure composition (% of alpha-helix, beta-sheet,
beta-turn, random coil, etc.) from the peptide bond region (far-
UV region, or “far-UV CD”)
 Tertiary structure ﬁngerprint from the CD spectra of aromatic
aa residues (near-UV region or “near-UV CD”).
1.2.4. Secondary Structure Calculation from Far-UV CD Spectra
Diﬀerent types of secondary structures give rise to characteris-
tic CD spectra in far-UV (below 250 nm), which diﬀer in their
peak positions and intensities.[55,56] Various empirical methods
have been developed for analyzing protein CD spectra for quan-
titative estimation of the secondary structure content. However,
reference database sets of proteins, with CD spectra matching to
secondary structure components derived from X-ray structures,
provide the key resource for this task. Thus, the most important
variable that contributes to the quality of the CD spectra analyses
for the prediction of protein secondary structure is the reference
database that is used.
1.2.5. Tertiary Structure Fingerprint from Near-UV CD Spectra
Analysis
The spectra in the region 260–320 nm arise from the aromatic
aas. The actual shape and magnitude of the near UV CD spec-
trum of a protein will depend on the number of each type of
aromatic aa present, their mobility, the nature of their environ-
ment, and their spatial disposition in the protein. The near UV
CD spectrum of a protein can be used to compare, for example,
wild type and mutant forms of proteins, but may also point to
food processing-induced changes in proteins.[57] It can also pro-
vide important evidence for the existence of ‘‘molten globule’’
states in proteins, which are characterized by practical absence of
near UVCD signals, due to highmobility of aromatic side chains.
These “molten globule” states are often present as intermediates
of thermal denaturation of globular proteins.[58]
Both, far and near CD spectra have been useful in monitor-
ing thermal stability of food allergens, i.e. thermal stability of
Cor a 14, the 2S albumin from hazelnut.[59] The eﬀects of high-
pressure/temperature treatment and pulsed electric ﬁeld treat-
ment on peanut Ara h 2 and 6 and apple Mal d 3 and 1b were ex-
amined by CD spectroscopy[60] and the results showed that novel
processing technologies had little eﬀect on the allergen struc-
ture. Both, far and near CD spectra were also useful in assessing
the eﬀects of high intensity ultrasound on the structure of beta-
lactoglobulin,major allergen of cow’smilk, conﬁrmingmoderate
eﬀects of the processing on protein’s fold and stability.[57]
1.2.6. Fourier Transform IR Spectroscopy in Structural
Characterization of Proteins
Fourier transform IR (FTIR) spectroscopy is another nondestruc-
tive technique for structural characterization of proteins and
polypeptides. The IR spectral data of proteins are interpreted in
terms of the vibrations of a structural repeat. The repeat units
in proteins give rise to nine characteristic IR absorption bands
(amides A, B and I–VII). Amide I bands (1700–1600 cm−1) are
the most prominent vibrational bands of the protein backbone,
and they relate to protein secondary structural components.[61]
The method has been widely applied to the secondary struc-
ture and structural dynamics analyses, assessment of confor-
mational changes, and stability studies of food proteins. FTIR
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measurement of secondary structure helps to assess protein ag-
gregation and stability, thus making this technique of strategic
importance in the food proteomic ﬁeld. Examples of applications
of FTIR spectroscopy in the study of structural features of food
proteins critical of nutritional and technological performance are
discussed in several review articles.[62] It has been shown that in-
creasing the temperature clearly aﬀects the shape of the amide I
band in FTIR and indicates formation of beta-structures. These
data show that denaturation of peanut Ara h 1 leads to a more
structured conformation of the protein and explains the obser-
vation that Ara h 1 aggregates upon heating, a process that is
known to coincide with the formation of antiparallel beta-sheet
structures.[63] Aggregation of allergens at elevated temperatures
also prevents recording of far-UV CD spectra. Therefore, FTIR is
the method of choice for conﬁrming structural features of aggre-
gated and poorly soluble proteins.
1.2.7. Tertiary Structure Determination Methods
X-Ray and NMR in Solution: Protein tertiary structure (3D) has
been investigated using a number of spectroscopic approaches
such as X-ray crystallography, NMR, and MS. X-ray crystal-
lography is the most powerful method to obtain information
about the tertiary structure of proteins at the atomic level. In
the recent past improvement of computational technologies and
the development of new and powerful computer programs to-
gether with the enormous increment in the number of pro-
tein structures deposited in the Protein Data Bank (PDB), fa-
cilitated the resolution of new structures.[64] X-ray crystallogra-
phy provides detailed, atomic-level information about a protein
structure. However, it is not always possible to obtain crystals
of the required quality for such analysis. NMR oﬀers a reason-
able alternative to X-ray crystallography for low-molecular-weight
proteins.[65]
Our understanding of allergens has greatly improved due to
large sets of proteins being crystallized and/or resolved by NMR
and their structures deposited in the PDB.[66] The ﬁrst enzyme
structure to be determined was lysozyme, which happens to be
the chicken allergen, Gal d 4.[67]
In addition to the information obtained on the structure of in-
dividual allergens, structure analyses of allergens in complexes
with their natural ligands were also performed.[35,68,69] These
X-ray structures of molecular complexes allow to identify the
atoms involved in the molecular interactions between allergens
and molecules of our immune system. These complexes in-
clude peptides presented byMHCclass IImolecules,[70] cytokines
bound to their receptors,[71] allergen–antibody complexes,[72,73]
and innate immune receptors with their ligands.[74] Determina-
tion of the 3D structure of allergens has revealed the existence
of new structural groups of proteins. Alt a 1, the major aller-
gen from Alternaria alternata, has a unique beta-barrel structure
that forms a ‘‘butterﬂy-like’’ dimer and is exclusively found in
fungi.[75] The cockroach allergen, Bla g 1, has an alpha-helical
structure thus far only found in insects.[27] For some of impor-
tant food allergens, such as Ara h 2, X-ray structure was solved
in a form of hybrid expressed with mannose-binding protein
(MBP).[76]
1.2.8. Computational Methods in Prediction of Tertiary Structure
Due to the advances in computational methods and the steadily
growing number of protein data bank (PDB) entries, predict-
ing protein structures, based only on aa sequence becomes a
reasonably fast, simple, and reliable method. The methods of
computational prediction rely on modeling based on structural
similarity of aa sequences between target protein and a homol-
ogous protein of known 3D structure. There are webservers
available, such as the IntFOLD webserver, which provides a
simple uniﬁed interface that aims tomake complex proteinmod-
eling data more accessible to life scientists.[77] Molecular mod-
eling of three tegumental allergen-like proteins from Schisto-
soma mansoni showed that despite similarities in the domain
organization, there are diﬀerences in the structures of the three
proteins.[78] Three-dimensional models of the major vicilin aller-
gens from peanut (Ara h 1), lentil (Len c 1), and pea (Pis s 1), were
built by homology-based modelling from the X-ray coordinates
of the structurally closely related soybean beta-conglycinin.[79]
In addition, before the structure of Ara h 2 was solved by X-
ray crystallography, its 3D structure was modeled from Ara
h 6 (a homologous peanut allergen), which was solved by
NMR.[80]
1.3. Speciﬁc Serum Screening–IgE Binding Assays
Food allergic reactions are built up in two phases. After the ﬁrst
encounter with a given food source the predisposed individual
mounts a Th2 dominant immune response and produces aller-
gen speciﬁc IgE antibodies, called sensitization phase. After re-
peated exposure to the same allergenic source the IgE antibodies
present on the surface of mast cells recognize the speciﬁc aller-
gen, cross-link, and activate mast cells to release their biogenic
amines (e.g. histamine) and immunoactive substances,[81] which
then cause local or systemic symptoms, termed eﬀector phase.
It is generally accepted that allergic sensitization comprises the
presence of serum derived IgE antibodies and does not always
coincide with allergic symptoms.
Speciﬁc serum screening, that is using serum from an indi-
vidual sensitized to a given food source, can be performed by
diﬀerent in vitro assays. Depending on the assay a qualitative or
quantitative evaluation can be obtained. All in vitro IgE tests re-
quire a reference protein (puriﬁed and well characterized natural
or recombinant allergen) or extract (standardized reference ex-
tracts) and anti-IgE antibodies highly speciﬁc for this isotype.[82]
To assess the overall lgE binding activity of an extract, Western
blots provide information about IgE binding proteins on a quali-
tative level (e.g., size and presence of diﬀerent proteins). Primary
separation of proteins can be done one- or two-dimensionally.
ELISA assays allow an overall quantiﬁcation of IgE binding ca-
pacity to a target extract. Also diagnostic assays used for clini-
cal routine can be applied to assess the IgE binding activity of
a novel food source or puriﬁed proteins thereof. These routine
tests are available in diﬀerent formats. In principle, the extract or
single proteins are immobilized to a solid phase capturing spe-
ciﬁc antibodies from serum samples. Subsequently, bound IgE
is detected and quantiﬁed by labeled anti-IgE antibody detection
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reagent, e.g. enzyme conjugatedmonoclonal anti-IgE antibodies.
Some solid phase assays can adsorb high amounts of single pro-
teins or extracts, whereas others use a microarray format, spot-
ting a high number of minute amounts of individual highly pure
allergens simultaneously. Depending on the assay the required
amount of serum varies between 30 μL up to 120 μL. Appropri-
ate controls and reference protein batches need to be tested in
parallel (puriﬁed natural or recombinant allergens, standardized
extracts, etc.). While some tests provide absolute quantiﬁcation
of speciﬁc IgE, others, such as the microarray approaches, allow
semiquantitative assessment of IgE antibody concentrations.
IgE binding and cross-linking by allergens can also be analyzed
using functional in vitro, ex vivo, and in vivo testing. Cellular in
vitro or ex vivo assays such as basophil activation test (BAT) can be
performed to conﬁrm functional IgE binding. Upon stimulation
with allergens or extracts cellular activation is measured either by
mediator release or upregulation of cellular surface molecules.
In this assay allergens and extracts in diﬀerent buﬀers can be
tested. In vivo, skin prick testing and oral food challenges can
be performed. Skin prick testing (SPT), veriﬁes speciﬁc mast cell
degranulation. This test is applied in clinical routine diagnosis,
using total extracts or the target food source on human skin. Af-
ter 15min a wheal and ﬂare reaction can be observed as a positive
test result. For clinical diagnosis puriﬁed recombinant allergens
are not applied in SPTs due to regulatory issues. However, SPTs
demonstrate allergic sensitization, but the correlation to clinical
symptoms is limited. Oral food challenges (OFCs), including the
double blind placebo controlled food challenge (DBPCFC), which
is considered the gold standard of food allergy diagnosis, is also
an option to be included in allergenic risk assessment. However,
these tests are time and cost consuming and are restricted to spe-
cializedmedical centers. Since uniform standardized procedures
are lacking, the test outcomes are diﬃcult to compare. Therefore,
harmonized test protocols and validated challenge materials are
needed.[82]
If a novel food is introduced into the diet, it may induce aller-
gic reactions in already sensitized individuals due to the pres-
ence of cross-reactive proteins.[25] Alternatively, it may contain
novel allergens, and thus induce allergic reactions. While cross-
reactions will appear rather quickly after ﬁrst contacts, de novo
sensitizations will be recognized later. For allergenic risk assess-
ment cross-reactivity can be assessed using sera from already
sensitized donors, while for de novo sensitization this is not
possible.
For allergenic risk assessment the availability of well-deﬁned
patients’ sera is a limiting factor for IgE based in vitro assays.
Especially for novel foods where no previous allergic sensitiza-
tions have been reported these assays can only be performed
to check for potential cross-reactivity based on sensitization to
well-known allergens such as proﬁlins, Bet v 1-homologues,
nsLTPs, etc. Regarding the risk of de novo sensitization to pre-
viously unknown allergens, there is a need to develop new as-
says, such as cellular tests following sensitization, or identifying
physicochemical parameters of proteins highly relevant for aller-
gic sensitization. Also animal derived speciﬁc antibodies can be
produced and applied in immunological tests (ELISA, Western
blots). For allergenic risk assessment of novel foods, post market
monitoring could help to investigate the potential risks of novel
foods.
1.4. Pepsin Resistance and In Vitro Digestibility Tests
In order to understand the allergic response, it is important to
study the impact of digestion on food allergens, with regard to
their structural integrity to induce T-cell diﬀerentiation and IgE-
mediated activation of eﬀector cells after gastrointestinal transit.
In 1996, Astwood et al. developed a protocol for digestion stud-
ies using simulated gastric ﬂuid containing the enzyme pepsin
in order to discriminate between nonallergenic and allergenic
proteins.[83]
However, further studies are hesitant on the use of pepsin
resistance as a criterion for predicting allergenicity, as it has
been shown that many allergenic proteins are not more resistant
than nonallergenic ones.[84,85] The apparent stability of a protein
may vary depending on the experimental conditions used (pH,
pepsin–protein ratio, purity, and chemical environment). In ad-
dition, food processing and components of the food matrix can
drastically aﬀect the digestion of allergens.[86] Therefore, more
complex models than pepsinolysis, generally multiphasic, con-
sidering relevant factors in the physiological digestion, have been
developed.[87–90] Nevertheless, there is a lack of correlation be-
tween digestibility and allergenicity, probably due to the diﬀer-
ent conditions of digestion assays. In order to consolidate condi-
tions for simulated digestion, a harmonized digestion model has
been recently proposed.[91] However, this model was not yet used
to measure the diﬀerence between the digestibility of allergenic
and nonallergenic proteins.
In addition to diﬀerent experimental protocols, diﬀerent in-
terpretation of the results, could explain the disparity of results.
Thus, for example, Prs-1 avocado allergen is fully digested in sim-
ulated gastric ﬂuid in less than 1 min; however, the resulting
peptides retain their IgE-binding epitopes and exhibit a reactivity
similar to that of the intact protein both in vitro and in vivo.[92]
This highlights the importance of using high-resolution analyti-
cal techniques combined with more sensitive detectionmethods,
as well as a reference set of allergens in tests.[93]
Although the resistance to digestion is regarded as one of the
common properties of food allergens, digestibility does not pro-
vide suﬃcient information for allergenicity prediction, so the
study of the impact of the digestion process, at a molecular level,
is still essential to analyze the remaining protein or polypeptide
structures that could play a role in sensitizing or symptom trig-
gering.
1.5. Selected Examples for Well-Known Allergens and Novel
(Potentially Allergenic) Proteins
When assessing the allergenicity of a novel food or food protein,
we can generally describe two major cases: (1) The novel food
or food protein likely contains pan-allergenic and thus poten-
tially sensitizing and/or cross-reactive structures. (2) By contrast,
no comparative information about potential sensitizing or cross-
reactive structures is available, therefore the allergenic potential
of the novel food or protein is completely unknown. Both scenar-
ios will be further discussed.
According to structural, biochemical, and functional character-
istics, the so far identiﬁed allergenic proteins are found within a
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fairly limited number, i.e. approximately 2%, of protein families
compared to all known protein families.[23] Of the plant-derived
foods, the most frequent allergens are among the prolamin and
cupin superfamilies, the proﬁlins, and within the pathogenesis-
related PR-10 protein family. Examples are allergenic globulins
and albumins of seed storage proteins, ns-LTP, and proteins re-
lated to the major birch pollen allergen Bet v 1.[23] Among the
animal-derived foods, allergens are frequently found within the
protein families of tropomyosins, EF-hand proteins, lipocalins,
caseins, and serum albumins.[23,94]
Thus, when assessing allergenicity of novel foods or pro-
teins that likely contain or constitute proteins within the above
mentioned protein families with known allergenic potential, the
methods described in this paper can be used to gain knowledge
about the similarity to known allergens, the inherent stability to
allow substantial interaction with the immune system, and the
presentation of functional, and thus potential allergenic epitopes.
Accordingly, allergenic risk assessment has been based on meth-
ods to perform compositional analysis, to elucidate the primary
protein sequence and secondary and tertiary structural elements,
to investigate resistance against simulated gastric digestion, and
to clarify in a targeted approach of the IgE binding and cross-
linking properties of the novel food protein(s).
One such example where novel allergenic structures were
identiﬁed in novel plant foods is the study of Gubesch and
colleagues[95] about three exotic vegetables from Africa, Asia, and
South America that have not been commonly consumed in the
EU, namely water spinach (Ipomea aquatica; Convolvulaceae),
hyacinth bean (Lablab purpureus, syn.Dolichos lablab; Fabaceae),
and Ethiopian eggplant (Solanum gilo; Solanaceae). The authors
applied a three-step procedure that included (1) the identiﬁca-
tion of pan-allergenic structures, (2) the veriﬁcation of in vitro
IgE-binding capacity of these structures, and (3) in vivo veriﬁ-
cation of functional mediator release using SPT, and OFC with
the novel vegetables upon positive SPT. Pan-allergenic structures
were identiﬁed by immunoblot analyis with cross-reactive an-
imal antibodies immunized against PR-10 proteins, proﬁlins,
LTPs, and allergenic legume storage proteins. The targeted in
vitro screening of IgE binding to the vegetable total protein
extracts was accomplished with serum IgE from subjects al-
lergic to Fabaceae and Solanaceae foods, Mediterranean food
allergics with LTP sensitization, and subjects having multiple
pollen-associated food allergies. SPT and OFC were done in sub-
jects with pollen (grass, birch, and mugwort) allergy but who
had not been exposed to the three novel vegetables before. In
summary, proﬁlin and LTP were ﬁrst identiﬁed by animal anti-
bodies in all vegetables, and a Bet v 1 homologue in hyacinth
bean. Second, IgE-binding to LTP, proﬁlin, and a Bet v 1 homo-
logue was proven by immunoblot analysis and EAST (Enzyme-
Allergosorbent-Test). Third, positive SPT and OFC results were
observed for all vegetables in the pollen-allergic patients. Thus, in
vivo testing proved the potential of the novel vegetables to elicit
clinical allergy and veriﬁed the in vitro ﬁndings.
Another striking example of a novel allergenic animal food is
the insect Yellow mealworm (Tenebrio molitor) protein[96] where
pan-allergenic structures were identiﬁed and their IgE-binding
and cross-linking properties demonstrated. The authors used
approaches as advised by EFSA for allergenicity assessment.
Making use of LC–MS/MS, a large number of proteins in Yel-
low mealworm extracts (YMP) was identiﬁed, among which
tropomyosin (TM), and arginine kinase (AK) are proteins already
identiﬁed as major or important allergens in e.g. crustaceans. In
silico analysis of the identiﬁed aa sequences, using AllermatchTM
against the UniProt database, and applying the criteria of >35%
identity within an 80 aa sliding window, suggested several hits
for known allergens of mites and insects. It is worth noting that
mites, insects, and crustaceans are taxonomically closely related
and belong to the arthropods. As, e.g. TM and AK are considered
pan-allergenic structures in arthropods, individuals with allergies
to other arthropods such as crustacean or house dustmite (HDM)
might be at risk when consuming YMP. Consequently, the au-
thors demonstrated in vitro IgE binding and functional basophil
activation of YMP in patients with crustacean and HDM allergy,
and AK and TM were identiﬁed as major cross-reactive allergens
in YMP. Finally, simulated gastric ﬂuid digestion proved a mod-
erate stability of YMP. The demonstrated realistic possibility that
HDM and Crustacean allergic patients may react to food contain-
ing YMP was further veriﬁed in an in vivo follow-up study.[97] In
DBPCFC, 13 of 15 patients allergic to shrimp reacted positive to
mealworm. A comparison of individual eliciting doses of four pa-
tients who also had a shrimp challenge indicated that the eliciting
doses as well severity were in the same range for Yellow meal-
worm and shrimp. In conclusion, the in vivo testing proved the
potential of the novel insect protein to elicit clinical allergy and
veriﬁed the in vitro ﬁndings.
Both examples about the identiﬁcation of known allergenic
structures lead to the conclusion of a realistic possibility of clin-
ical cross-reactivity in subjects with preexisting allergy to these
structures. Obviously, this approach fully depends on targeted
screening based on the potential allergenicity of known allergenic
structures.
By contrast, any novel protein without structural, biochemi-
cal, or functional relationship cannot be assessed for potential
allergenicity with the methods described in this paper. Other ap-
proaches are needed that can investigate the sensitizing potential,
such as dendritic cell activation ormousemodels, to discriminate
between allergens and nonallergens.[5,98]
Moreover, it needs to be emphasized that even the identi-
ﬁcation of known allergenic or pan-allergenic structures does
not necessarily prove allergenicity. A well-known example is
coiled-coil-superhelical TM, an invertebrate pan-allergen,[99] but
a nonallergen in vertebrate meat such as from beef, pork, or
chicken.[100] The identities between nonallergenic vertebrate and
allergenic invertebrate tropomyosins are below 60%. By con-
trast, the identities of nsLTPs from peach and kiwi may be com-
parably low but IgE cross-reactivity is retained.[101] Further, the
substitution of only 12 aa of the allergenic TM, Pen a 1 from
Brown shrimp toward vertebrateTMs, while retaining the sec-
ondary structure as assessed by CD spectroscopy leads to 90–98%
reduction of allergenicity as measured in functional speciﬁc me-
diator release from humanized rat basophilic leukemia cells.[102]
These 12 aa resemble only 4% diﬀerence in aa identity.
A similar example can be found within the PR-10 protein
family. The major birch pollen allergen, Bet v 1, is considered
the primary sensitizer in birch-associated soybean allergy. Al-
lergic reactions to soybean in birch pollen allergic subjects are
mediated by the homologous soybean allergen, Gly m 4.[103]
For IgE binding, the conserved fold is required.[104] By contrast,
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Norcoclaurine synthase (NCS) frommeadow rue, which is struc-
turally homologous to Bet v 1 does not bind Bet v 1[105] or Gly m 4
speciﬁc IgE.[104] By grafting a very limited number of critical aa
residues of IgE-binding surface areas of Bet v 1 or Gly m 4 onto
NCS, IgE binding is induced.
In summary, the mere structural relationship or degree of aa
identity does not seem to explain the diﬀerences in allergenicity.
Thus, aa identity and structural homology alone are weak pre-
dictors in allergenicity risk assessment of novel foods, and addi-
tional tests are needed to assess their allergenic potential.
2. Summary and Conclusions
There is an increasing need for novel food sources to feed a grow-
ing population while ensuring safe human consumption. There-
fore, a potentially increased allergenic risk of novel foods has to
be assessed. With the use of up to date analytical techniques, pri-
mary, secondary, and tertiary structures of proteins can be investi-
gated down to a molecular level. For the allergenic activity assays
are available, using either IgE antibodies derived from patients’
sera or antibody sera raised in animals. Also, cellular assays pro-
vide evidence of functional allergenic activity of food proteins. In
addition, digestion assays have been used to investigate the sta-
bility of proteins as another indicator of potential allergenicity,
and food processing and food matrix interaction with allergenic
proteins is considered to impact on allergenicity, too. In paral-
lel, databases collating sequences and their physicochemical and
immunological features have evolved, facilitating the search for
homologous proteins and peptides.
For the current risk assessment strategies it has to be clearly
stated that not a single method is available to predict allergenicity
between a novel allergenic versus nonallergenic molecule, both
at the sites of elicitation and sensitization. Therefore, a weight of
evidence approach is needed. Furthermore, the established and
currently applied methods are based on a homology assessment
to already identiﬁed allergens. Thus, these methods are of lim-
ited applicability for novel proteins lacking homology to already
identiﬁed proteins. Independently, even for the well-established
methods used in allergenicity risk assessment of homologous
proteins, we have identiﬁed limitations or gaps of knowledge (Ta-
ble 2) which should be addressed in the future. For example,
various protocols exist for the performance of IgE-binding as-
says, digestion assays, and biological assays. Certainly, there is
a need for harmonization of protocols or at least guidance in
calibrating the assays with appropriate reference proteins that
present low and high allergenicity, respectively. The identiﬁca-
tion and availability of such reference proteins may help com-
paring data sets obtained by the various assays. Inclusion crite-
ria for allergenic proteins in databases should be harmonized
for better comparability and sound data mining. Experiment-
based knowledge about allergenic B- and T-cell epitopes or mi-
motopes is still limited. Availability of such knowledge in aller-
gen databases may allow improving algorithms for prediction
of a sensitizing potential of proteins independent of basic struc-
tural homology. Collaborative ring trials should determine the ro-
bustness of individual techniques, ideally performed in a blinded
setting. More data on how food processing, and food matrix in-
teraction such as ligand binding, modify the allergenicity of pro-
teins, are required if such knowledge should be used in predictive
models.
For the allergenic risk assessment of novel foods or food pro-
teins without homology to known allergenic structures, addi-
tional cellular (e.g. dendritic cell) assays and animal models need
to be developed and validated, ideally using known allergenic
and known nonallergenic reference proteins of nonhomologous
sources. Within the COST action Improving Allergy Risk As-
sessment Strategy for New Food Proteins (ImpARAS), a partner-
ship including academia, industry, stakeholders, and regulators,
the gaps of the current risk assessment using established tech-
niques are addressed, and the practical implications of existing
and future test procedures and parameters will be discussed. Fur-
ther, the COST action ImpARAS will work toward novel strate-
gies to better predict safe consumption of novel foods based
on the ﬁndings about the underlying immunological mecha-
nisms of an allergic response, especially addressing the event of
sensitization.
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